Dr. Reddy’s Laboratories (RDY) to Release Earnings on Tuesday

Dr. Reddy’s Laboratories (NYSE:RDY) will likely be releasing its Q2 25/26 results before the market opens on Tuesday, November 4th. Analysts expect Dr. Reddy’s Laboratories to post earnings of $0.18 per share for the quarter. Interested persons may visit the the company’s upcoming Q2 25/26 earningresults page for the latest details on the call scheduled for Friday, October 24, 2025 at 10:00 AM ET.

Dr. Reddy’s Laboratories (NYSE:RDY) last announced its quarterly earnings results on Friday, October 24th. The company reported $0.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.18 by $0.01. The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $944.26 million. Dr. Reddy’s Laboratories had a net margin of 17.14% and a return on equity of 17.13%. On average, analysts expect Dr. Reddy’s Laboratories to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Dr. Reddy’s Laboratories Stock Performance

Shares of RDY opened at $13.31 on Monday. The company has a 50-day simple moving average of $14.31 and a 200-day simple moving average of $14.43. The company has a quick ratio of 1.36, a current ratio of 1.85 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $11.11 billion, a PE ratio of 16.43, a P/E/G ratio of 6.22 and a beta of 0.40. Dr. Reddy’s Laboratories has a 52-week low of $12.26 and a 52-week high of $16.17.

Institutional Investors Weigh In On Dr. Reddy’s Laboratories

Several hedge funds have recently modified their holdings of the company. Osaic Holdings Inc. boosted its stake in shares of Dr. Reddy’s Laboratories by 1,105.3% during the 2nd quarter. Osaic Holdings Inc. now owns 11,390 shares of the company’s stock worth $158,000 after purchasing an additional 10,445 shares during the last quarter. Evergreen Capital Management LLC acquired a new stake in shares of Dr. Reddy’s Laboratories during the 2nd quarter worth about $441,000. Corient Private Wealth LLC boosted its stake in shares of Dr. Reddy’s Laboratories by 3.8% during the 2nd quarter. Corient Private Wealth LLC now owns 121,767 shares of the company’s stock worth $1,830,000 after purchasing an additional 4,410 shares during the last quarter. Vident Advisory LLC boosted its stake in shares of Dr. Reddy’s Laboratories by 18.3% during the 2nd quarter. Vident Advisory LLC now owns 189,269 shares of the company’s stock worth $2,845,000 after purchasing an additional 29,242 shares during the last quarter. Finally, Orion Porfolio Solutions LLC boosted its stake in shares of Dr. Reddy’s Laboratories by 38.6% during the 2nd quarter. Orion Porfolio Solutions LLC now owns 117,353 shares of the company’s stock worth $1,764,000 after purchasing an additional 32,664 shares during the last quarter. 3.85% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

RDY has been the topic of a number of research reports. Weiss Ratings reissued a “buy (b-)” rating on shares of Dr. Reddy’s Laboratories in a research note on Wednesday, October 8th. Zacks Research raised shares of Dr. Reddy’s Laboratories from a “strong sell” rating to a “hold” rating in a research note on Friday, August 15th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, Dr. Reddy’s Laboratories presently has an average rating of “Moderate Buy” and an average price target of $16.95.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.